GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Virbac SA (OTCPK:VRBCF) » Definitions » 3-Year EBITDA Growth Rate

VRBCF (Virbac) 3-Year EBITDA Growth Rate : 10.20% (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Virbac 3-Year EBITDA Growth Rate?

Virbac's EBITDA per Share for the six months ended in Dec. 2024 was $13.03.

During the past 12 months, Virbac's average EBITDA Per Share Growth Rate was 20.60% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 10.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 8.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 11.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Virbac was 32.40% per year. The lowest was -14.40% per year. And the median was 10.45% per year.


Competitive Comparison of Virbac's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - General subindustry, Virbac's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virbac's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Virbac's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Virbac's 3-Year EBITDA Growth Rate falls into.


;
;

Virbac 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Virbac  (OTCPK:VRBCF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Virbac 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Virbac's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Virbac Business Description

Traded in Other Exchanges
Address
13e rue LID - BP 27, Carros, FRA, 06511
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.

Virbac Headlines

From GuruFocus

Full Year 2018 Virbac SA Earnings Call Transcript

By GuruFocus Research 03-08-2024

Full Year 2021 Virbac SA Earnings Call Transcript

By GuruFocus Research 03-08-2024

Full Year 2019 Virbac SA Earnings Call Transcript

By GuruFocus Research 03-08-2024

Half Year 2021 Virbac SA Earnings Call Transcript

By GuruFocus Research 03-08-2024

Half Year 2022 Virbac SA Earnings Call Transcript

By GuruFocus Research 03-08-2024

Full Year 2020 Virbac SA Earnings Call Transcript

By GuruFocus Research 03-08-2024

Half Year 2020 Virbac SA Earnings Call Transcript

By GuruFocus Research 03-08-2024

Virbac SA SFAF Meeting Transcript

By GuruFocus Research 03-08-2024